Limitations of contemporary antidepressants: Tolerability

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 10, 2007, Pages 11-17

  Papakostas, George I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

ANXIETY DISORDER; BIPOLAR DEPRESSION; BONE MARROW DISEASE; CLINICAL TRIAL; DISTRESS SYNDROME; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERPROLACTINEMIA; HYPOMANIA; HYPONATREMIA; INSOMNIA; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; MEDICAL RESEARCH; MOOD DISORDER; MORBIDITY; MORTALITY; NAUSEA; NEUTROPENIA; PRIAPISM; PRIORITY JOURNAL; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SUICIDAL IDEATION; THROMBOCYTOPENIA; URINE RETENTION; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; OBESITY; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SUICIDE, ATTEMPTED; TIME FACTORS; WEIGHT GAIN;

EID: 34848883602     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65:959-965
2. Lin EH, Von Korff M, Lin E, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74
3. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66:974-981
4. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry 2006;51:783-790
5. Papakostas GI, Hornberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. J Psychopharmacol. In press
6. Beasley CM Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991;52:294-299
7. Falk WE, Rosenbaum JE, Otto MW, et al. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol 1989;2:208-214
8. Munizza C, Olivieri L, Di Loreto G, et al. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2006;22:1703-1713
9. Kasper S, Olivieri L, Di Loreto G, et al. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin 2005;21:1139-1146
10. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996;57(suppl 2):46-52
11. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(suppl 2):53-62
12. Berlanga C, Arechavaleta B, Heinze G, et al. A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients. Salud Mental 1997;20:1-8
13. Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998;44:3-14
14. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002;180:528-535
15. Nelson JC, Pritchett YL, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006;8:212-219
16. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind, placebo-controlled trial. J Clin Psychiatry 2002;63:225-231
17. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-470
18. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399
19. Perahia DGS, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006;21:367-378
20. Greist J, McNamara RK, Mallinckrodt CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004;29:1446-1455
21. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-181
22. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64
23. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-1196
24. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 2006;14:361-370
25. Nemeroff CB, Thase ME, for the EPIC 014 Study Group. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 2007;41:351-359
26. DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry 2003;64(suppl 18):14-19
27. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;30:57-71
28. Tylee A, Beaumont G, Bowden MW, et al. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Prim Care Psychiatry 1997;3:51-58
29. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998;59:352-357
30. McPartlin GM, Reynolds A, Anderson C, et al. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry 1998;693:127-132
31. Alves C, Cachola I, Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Psychiatry 1999;5:57-63
32. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999;60:22-28
33. Mehtonen OP, Sogaard J, Roponen P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 2000;61:95-100
34. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000;15:29-34
35. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002;5:115-120
36. Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-monfh comparative trial with citalopram. Int J Geriatr Psychiatry 2004;19:1123-1130
37. Sir A, D'Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005;66:1312-1320
38. Shelton RC, Haman KL, Rapaport MH, et al. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 2006;67:1674-1681
39. Ballus C, Quiros G, De Flores T, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000;15:43-48
40. Stahl SM, Mendels J, Schwartz GE. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. J Clin Psychopharmacol 2002;22:388-392
41. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006;60:1350-1355
42. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(suppl 6):33-37
43. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-194
44. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366
45. Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000;20:122-128
46. Coleman CC, Cunningham LL, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11:205-215
47. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006;51:234-242
48. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23:1040-1058
49. Weihs KL, Settle EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000;61:196-202
50. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997;58:532-537
51. Clayton AH, Zajecka J, Ferguson JM, et al. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 2003;18:151-156
52. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharm 2006;20:91-96
53. Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 2006;26:121-127
54. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61:656-663
55. Philipp M, Tiller JW, Baier D, et al. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults: the Australian and German Study Groups. Eur Neuropsychopharmacol 2000;10:305-314
56. Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003;23:358-364
57. Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 2003;18:133-141
58. Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005;19:137-146
59. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-692
60. Thase ME, Nierenberg AA, Keller MB, et al. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001;62:782-788
61. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998;13:63-73
62. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999;156:1170-1176
63. Emslie GJ, Heiligenstein JH, Hoog SL, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004;43:1397-1405
64. Gilaberte I, Montejo AL, de la Gandara J, et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001;21:417-424
65. Kornstein SG, Bose A, Li D, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:1767-1775
66. Fava M, Judge R, Hoog S, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000;61:863-867
67. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 2006;188:346-353
68. Wise TN, Perahia DG, Pangallo BA, et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 2006;8:269-278
69. Simon JS, Aquiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 2004;38:249-257
70. Montgomery SA, Entsuah R, Hackett D, et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 2004;65:328-336
71. Kamijima K, Burt T, Cohen G, et al. A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. Int Clin Psychopharmacol 2006;21:1-9
72. McGrath PJ, Stewart JW, Quitkin FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 2006;163:1542-1548
73. Lepine JP, Callaird V, Bisserbe JC, et al. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004;161:836-842
74. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-49
75. Klysner R, Bent-Hansen J, Hansen HL, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;181:29-35
76. Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001;178:304-310
77. Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000;61:851-857
78. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998;280:1665-1672
79. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Am J Psychiatry 1998;13:55-62
80. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10(suppl 1):29-35
81. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-195
82. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-188
83. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-222
84. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988;3:69-76
85. Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996;11:137-145
86. Sussman N, Ginsberg DL, Bikoff J, et al. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001;62:256-260
87. Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk of relapse for depression. Biol Psychiatry 2002;51:753-761
88. Thase M, Bartlett C. Reboxetine does not cause weight gain during long-term therapy [abstract]. Eur Neuropsychopharmacol 2001;11(suppl 3):S215
89. Papakostas GI, Miller KK, Petersen T, et al. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry 2006;67:952-957
90. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med 2004;164:327-332
91. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006;67:1754-1758
92. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-912
93. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-322
94. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-131
95. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-512
96. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210
97. Papp LA, Gorman JM. Suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:1380-1381
98. Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. N Engl J Med 1991;324:420
99. Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry 1991;52:108-111
100. Beasley CM Jr, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991;303:685-692
101. Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995;5:5-13
102. Letizia C, Kapik B, Flanders WD. Suicidal risk during controlled clinical investigations of fluvoxamine. J Clin Psychiatry 1996;57:415-421
103. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-1345
104. Apter A, Lipschitz A, Fong R, et al. Evaluation of suicidal thoughts and behaviors in children and adolescents taking paroxetine. J Child Adolesc Psychopharmacol 2006;16:77-90
105. Mosholder AD, Willy M. Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis. J Child Adolesc Psychopharmacol 2006;16:25-32
106. Pedersen AG. Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol 2005;20:139-143
107. GlaxoSmithKline Clinical Trial Register. Analysis of data in bupropion clinical trials for suicidality. Available at: http://ctr.gsk.co.uk/Summary/ bupropion/IV_suicide_observational.pdf. Accessed March 16, 2007
108. Beasley C, Disch D, Prabhakar V, et al. Potential predictive factors for development of treatment-emergent suicidal ideation in the fluoxetine placebo-controlled major depressive disorder database [poster]. Presented at the 45th annual meeting of the American College of Neuropsychopharmacology (ANCP); Dec 3-7, 2006; Hollywood, Fla
109. Pedersen AG. Citalopram and suicidality in adult major depression and anxiety disorders. Nord J Psychiatry 2006;60:392-399
110. Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006;26: 587-594
111. Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003;160:790-792
112. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006;26:203-207
113. Thase ME, Carpenter DJ, Fong R, et al. Suicidality in adult paroxetine depression studies [poster]. Presented at the 45th annual meeting of the American College of Neuropsychopharmacology (ANCP); Dec 3-7, 2006; Hollywood, Fla
114. Gupta S, Frank B, Madhusoodanan S. Risperidone-associated galactorrhea in a male teenager [letter]. J Am Acad Child Adolesc Psychiatry 2001;40:504-505
115. Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998;59:366-373
116. Loo WJ, Alexandroff A, Flanagan N. Bupropion and generalized acute urticaria: a further case. Br J Dermatol 2003;149:440
117. Liu X, Sahud MA. Glycoprotein IIb/IIIa complex is the target in mirtazapine-induced immune thrombocytopenia. Blood Cells Mol Dis 2003;30:241-245
118. Kasper S, Praschak-Rieder N, Tauscher J, et al. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997;17:251-264
119. Hutchison LC. Mirtazapine and bone marrow suppression: a case report. J Am Geriatr Soc 2001;49:1129-1130
120. Carvajal Garcia-Pando A, Garcia del Pozo J, Sanchez AS, et al. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002;63:135-137
121. Toofanny N, Maddens ME. Reversible penile priapism associated with nefazodone. J Am Geriatr Soc 2002;50:1610-1611
122. Fernandes NF, Martin RR, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. Am J Gastroenterol 2000;95:532-535
123. Bardin ED, Krieger JN. Pharmacological priapism; comparison of trazodone- and papaverine-associated cases. Int Urol Nephrol 1990;22:147-152
124. Irwin M, Spar JE. Reversible cardiac conduction abnormality associated with trazodone administration. Am J Psychiatry 1983;140:945-946
125. Combes A, Peytavin G, Theron D. Conduction disturbances associated with venlafaxine. Ann Intern Med 2001;134:166-167
126. Kasper S, Wolf R. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. Eur Neuropsychopharmacol 2002;12:119-122
127. Hanje AJ, Pell LJ, Votolato NA, et al. Case report: fulminant hepatic failure involving duloxetine hydrochloride. Clin Gastroenterol Hepatol 2006;4:912-917